BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23830352)

  • 1. Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival.
    Abu Saadeh F; Norris L; O'Toole S; Gleeson N
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):214-8. PubMed ID: 23830352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
    Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
    J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes.
    Duska LR; Garrett L; Henretta M; Ferriss JS; Lee L; Horowitz N
    Gynecol Oncol; 2010 Mar; 116(3):374-7. PubMed ID: 19922988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of silent venous thromboembolism before treatment in ovarian cancer.
    Satoh T; Oki A; Uno K; Sakurai M; Ochi H; Okada S; Minami R; Matsumoto K; Tanaka YO; Tsunoda H; Homma S; Yoshikawa H
    Br J Cancer; 2007 Oct; 97(8):1053-7. PubMed ID: 17895896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism in ovarian cancer.
    Rodriguez AO; Wun T; Chew H; Zhou H; Harvey D; White RH
    Gynecol Oncol; 2007 Jun; 105(3):784-90. PubMed ID: 17408726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer.
    Black D; Iasonos A; Ahmed H; Chi DS; Barakat RR; Abu-Rustum NR
    Gynecol Oncol; 2007 Oct; 107(1):66-70. PubMed ID: 17614125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival.
    Diaz ES; Walts AE; Karlan BY; Walsh CS
    Gynecol Oncol; 2013 Dec; 131(3):541-5. PubMed ID: 24041880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimizing tumor burden by extensive cytoreductive surgery decreases postoperative venous thromboembolism in ovarian clear cell carcinoma.
    Lim MC; Lee HS; Kang S; Seo SS; Lee BY; Park SY
    Arch Gynecol Obstet; 2010 Feb; 281(2):329-34. PubMed ID: 19458955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study.
    Tetsche MS; Nørgaard M; Pedersen L; Lash TL; Sørensen HT
    BMC Cancer; 2006 Jul; 6():189. PubMed ID: 16846496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
    Matsuo K; Hasegawa K; Yoshino K; Murakami R; Hisamatsu T; Stone RL; Previs RA; Hansen JM; Ikeda Y; Miyara A; Hiramatsu K; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Roman LD; Gabra H; Fotopoulou C; Sood AK
    Eur J Cancer; 2015 Sep; 51(14):1978-88. PubMed ID: 26238017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristic and prognostic implication of venous thromboembolism in ovarian clear cell carcinoma: a 12-year retrospective study.
    Ye S; Yang J; Cao D; Bai H; Huang H; Wu M; Chen J; You Y; Lang J; Shen K
    PLoS One; 2015; 10(3):e0121818. PubMed ID: 25793293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of venous thromboembolism occurrence in medical patients among the insured population.
    Spyropoulos AC; Hussein M; Lin J; Battleman D
    Thromb Haemost; 2009 Nov; 102(5):951-7. PubMed ID: 19888534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States.
    Khorana AA; Dalal M; Lin J; Connolly GC
    Cancer; 2013 Feb; 119(3):648-55. PubMed ID: 22893596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer.
    Sandhu R; Pan CX; Wun T; Harvey D; Zhou H; White RH; Chew HK
    Cancer; 2010 Jun; 116(11):2596-603. PubMed ID: 20336780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer and venous thromboembolic risk.
    Tateo S; Mereu L; Salamano S; Klersy C; Barone M; Spyropoulos AC; Piovella F
    Gynecol Oncol; 2005 Oct; 99(1):119-25. PubMed ID: 15990161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival.
    Abu-Rustum NR; Richard S; Wilton A; Lev G; Sonoda Y; Hensley ML; Gemignani M; Barakat RR; Chi DS
    Gynecol Oncol; 2005 Nov; 99(2):320-6. PubMed ID: 16061278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incidence, risk factors, and prognosis of recurrent venous thromboembolism (VTE) in patients with advanced solid cancers receiving anticoagulation therapy after the diagnosis of index VTE.
    Yhim HY; Jang MJ; Kwak JY; Yim CY; Choi WI; Lee YC; Lee JO; Lee KW; Bang SM; Kim SH; Kim YK; Chang HJ; Oh D;
    Thromb Res; 2013 Apr; 131(4):e133-40. PubMed ID: 23399441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery.
    Rollins KE; Peters CJ; Safranek PM; Ford H; Baglin TP; Hardwick RH
    Eur J Surg Oncol; 2011 Dec; 37(12):1072-7. PubMed ID: 21925829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors.
    Wun T; White RH
    Cancer Invest; 2009; 27 Suppl 1():63-74. PubMed ID: 19291526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venous thromboembolism in advanced ovarian cancer patients undergoing frontline adjuvant chemotherapy.
    Pant A; Liu D; Schink J; Lurain J
    Int J Gynecol Cancer; 2014 Jul; 24(6):997-1002. PubMed ID: 24905613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.